Výsledky vyhledávání - "BJ Montoro Ronsano"

4CPS-121 Evaluation of cost and efficacy of eculizumab in complement mediated thrombotic microangiopathy in the clinical setting

Autor: BJ Montoro Ronsano, N Ramos Terrada, C Alerany Pardo, P. Sanchez-Sancho, M Larrosa García, S Garcia Garcia

Publikováno v: Section 4: Clinical Pharmacy Services.

Background and importance Complement mediated thrombotic microangiopathy (C-TMA) is caused by complement disruption that leads to haemolysis and thrombocytopenia. Eculizumab inhibits C5b-9 complex formation by binding protein C5 and has been approved

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca092308850fcbe28d2ea088cdc4a89d
https://doi.org/10.1136/ejhpharm-2020-eahpconf.222

Zobrazit plný text záznamu

5PSQ-016 Tolvaptan associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease

Autor: M Larrosa García, BJ Montoro Ronsano, I Agraz Pamplona, RP Bury Macias

Publikováno v: Section 5: Patient Safety and Quality assurance.

Background and importance Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that causes kidney damage; the treatment goal is to postpone renal failure. The only specific treatment approved for ADPKD is tolvaptan (Jinarc, Otsu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f6ca099588afd3fde40e82afacd59c2
https://doi.org/10.1136/ejhpharm-2020-eahpconf.333

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání